Clinical trial: Association between early disease clearance and long-term outcomes—4-year results from the Phase 3 UNIFI study of ustekinumab in ulcerative colitis
Alimentary Pharmacology & Therapeutics 2025;62:483–492 Doi: 10.1111/apt.70264
Danese et al. showed that patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long-term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. Authors evaluated disease clearance in the Phase 3 UNIFI program and its association with long-term outcomes.
Disease clearance was achievable with ustekinumab IV induction and SC maintenance treatment in patients with moderately to severely active UC. Danese et al. present one of the first prospective studies that support the role of disease clearance in predicting long-term treatment efficacy in UC.
